ImmunityBio, Inc.
NASDAQ:IBRXBiotechnology
Healthcare
$6.57 +2.58%
+$0.18 today
- Market cap
- $6.99B
- Beta
- 0.10
- P/E (TTM)
- -8.6
- EPS (TTM)
- -$0.83
52W Low $1.95High $12.43
Volume 11.10M
Average 16.40M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$304.94M
FY 2025 · Annual
Investing Cash Flow
-$149.80M
FY 2025 · Annual
Financing Cash Flow
$400.24M
FY 2025 · Annual
+42.1% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (346.79M) | (416.57M) | (583.85M) | (413.65M) | (351.47M) |
| Depreciation & Amortization | 14.24M | 18.26M | 18.51M | 17.55M | 15.53M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 57.18M | 40.18M | 49.16M | 34.43M | 36.81M |
| Change in Working Capital | (15.4M) | (16M) | 3.83M | (19.42M) | (54.33M) |
| Accounts Receivables | 0 | 0 | 0 | (2.36M) | (40.21M) |
| Inventory | 0 | 0 | 0 | (8.27M) | (6.33M) |
| Accounts Payables | 0 | 0 | (6.48M) | (3.17M) | (190K) |
| Other Working Capital | (15.4M) | (16M) | 10.3M | (5.62M) | (7.6M) |
| Other Non-Cash Items | 16.35M | 36.62M | 145.44M | (10.16M) | 48.53M |
| Operating Cash Flow | (274.42M) | (337.51M) | (366.76M) | (391.24M) | (304.94M) |
| Capital Expenditures | (33.56M) | (78.16M) | (30.58M) | (6.89M) | (3.85M) |
| Acquisitions (Net) | 0 | 0 | 0 | (1M) | 0 |
| Purchases of Investments | 0 | 0 | (10.36M) | (140.22M) | (241.37M) |
| Sales of Investments | 0 | 0 | 10.47M | 136.61M | 95.82M |
| Other Investing Activities | (51.32M) | 105.46M | 0 | (747K) | 0 |
| Investing Cash Flow | (84.89M) | 27.3M | (30.47M) | (12.25M) | (149.8M) |
| Debt Repayment | 338.5M | 174.07M | 451.39M | 96.89M | 1.72M |
| Common Stock Issued | 0 | 0 | 110.4M | 111.36M | 400.78M |
| Common Stock Repurchased | (4.06M) | (616K) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 171.01M | 60.16M | (3.44M) | 73.38M | (2.27M) |
| Financing Cash Flow | 505.44M | 233.61M | 558.34M | 281.63M | 400.24M |
| Effect of Forex Changes | 48K | 284K | (292K) | (23K) | 15K |
| Net Change in Cash | 146.19M | (76.32M) | 160.82M | (121.88M) | (54.48M) |
| Free Cash Flow | (307.98M) | (415.67M) | (397.34M) | (398.12M) | (308.78M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$351.5M
+ D&A$15.5M
+ Stock-Based Comp$36.8M
+ Deferred Tax$0
- Working Capital-$54.3M
+ Other Non-Cash$48.5M
= Operating Cash Flow-$304.9M
- Capex-$3.8M
= Free Cash Flow-$308.8M
Analysis
FY2025 free cash flow is -$308.8M. FCF conversion is 87.9% of net income. Operating cash flow was -$304.9M, with capex of -$3.8M. The largest bridge item is Working Capital at -$54.3M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 9, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| 8-K | Current report | Oct 14, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 6, 2026 |
Does IBRX generate free cash flow?
ImmunityBio, Inc. (IBRX) generated -$308.78M of free cash flow in fiscal 2025.
How much operating cash flow does IBRX produce?
Operating cash flow was -$304.94M, before capital expenditures of $3.85M.
Continue the stock analysis
Jump to another research area for this company.